Unixell Biotech Achieves FDA Clearance for Revolutionary Epilepsy Cell Therapy

Unixell Biotech Achieves FDA Clearance for Groundbreaking Epilepsy Cell Therapy

On March 12, 2026, Unixell Biotech reached a pivotal milestone by securing Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its innovative allogeneic iPSC-derived cell therapy, UX-GIP001, aimed at treating focal epilepsy. This clearance marks UX-GIP001 as the first of its kind in the U.S. and highlights China's initial foray into clinical trials for epilepsy through this advanced cell therapy.

Epilepsy is a prevalent neurological condition that affects more than 70 million people globally. It can manifest in individuals of all ages but is particularly common among infants and the elderly. The disorder can be triggered by various factors, including brain injuries, surgical trauma, or unknown causes. Current treatment options, such as surgical resection and neurostimulation, often come with adverse side effects, demonstrating a critical need for innovative therapies that can effectively target epileptic foci while safeguarding healthy brain tissue.

In those suffering from epilepsy, the dysfunction of GABAergic interneurons contributes significantly to the hyperexcitability of neural circuits, leading to disruptive seizures. UX-GIP001 addresses this issue through Unixell's proprietary stem cell technologies, which enable the production of inhibitory neural progenitor cells using a directed differentiation process. Post-transplantation, these cells work to rebuild inhibitory neural networks, thereby suppressing seizure activity.

Preclinical studies have already validated the effectiveness of UX-GIP001 in animal models for epilepsy, while also confirming a solid safety profile. As a result, Unixell Biotech is confidently moving forward to inaugural clinical trials, with a Phase 1 study targeting safety, tolerability, and efficacy for patients suffering from drug-resistant epilepsy.

With the addition of UX-GIP001 to its portfolio, Unixell Biotech is solidifying its dedication to addressing significant unmet medical needs, particularly in areas such as Parkinson’s disease and epilepsy. The company is uniquely positioned to advance both autologous and allogeneic cellular therapies, further reinforcing its diverse product lineup designed for various medical conditions.

Utilizing its leading research and development platform for human pluripotent stem cells, along with an advanced neural cell differentiation technology, Unixell Biotech is relentlessly working to enhance its capabilities in cell drug development. Drawing on robust scientific foundations, the company aspires to build a long-lasting, innovative cellular therapy platform that aims to provide safer and more effective treatment alternatives for patients across the globe.

About Unixell Biotech

Founded in 2021, Shanghai UniXell Biotechnology Co., Ltd. specializes in cell therapy drug development targeting neurological disorders such as Parkinson’s disease and epilepsy. The company boasts a state-of-the-art 4,000-square-meter research and development center, alongside Good Manufacturing Practice (GMP) facilities.

UniXell has cultivated four innovative technology platforms focused on reprogramming technology, stem cell differentiation, SISBAR lineage tracing technology, and high-precision gene editing. These platforms enable the consistent development and production of superior quality neural cell therapies, leading to more effective clinical outcomes.

Furthermore, the firm has successfully attracted significant investments from prominent organizations such as Hillhouse Capital, CDH Investments, Fosun Group, Sherpa Healthcare Partners, TF Capital, and Tasly Capital, providing a testament to the market's confidence in its pioneering therapeutic solutions.